Ankylosing Spondylitis Market – By Treatment (NSAIDs, Biologic Therapies [TNF, IL-17 Inhibitors], JAK Inhibitors), Route of Administration (Parenteral, Oral), Type (Prescription, OTC), Application, Distribution Channel, Global Forecast (2024 – 2032)

Ankylosing Spondylitis Market – By Treatment (NSAIDs, Biologic Therapies [TNF, IL-17 Inhibitors], JAK Inhibitors), Route of Administration (Parenteral, Oral), Type (Prescription, OTC), Application, Distribution Channel, Global Forecast (2024 – 2032)

Ankylosing Spondylitis Market Size

To get key market trendsAnkylosing Spondylitis Market size accounted for USD 5.9 billion in 2023 and is anticipated to showcase growth at 8.2% CAGR from 2024 to 2032, due to increasing prevalence of ankylosing spondylitis. The improved diagnostic techniques have led to more cases being diagnosed

  Download Free Sample

Additionally, patient education initiatives have raised awareness about the disease among both patients and healthcare providers, resulting in earlier diagnosis and timely treatment. Thus, a combination of factors, including advancements in treatment options, increasing prevalence and awareness of the disease, and improved diagnostic methods significantly contributes to the market growth.
 

What are the growth opportunities in this market?

 Download Free Sample

Furthermore, advancements in treatment options have significantly impacted the ankylosing spondylitis market. The introduction and widespread adoption of biologic therapies, such as TNF inhibitors and IL-17 inhibitors, have transformed the management of ankylosing spondylitis by improving patient outcomes. Moreover, the development of JAK inhibitors has also provided new treatment options for patients who do not respond to conventional therapies, further driving market growth.

Ankylosing spondylitis (AS) is a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints, causing persistent pain, stiffness, and eventual fusion of joints. It often starts with inflammation in the lower back and can progress to other joints and ligaments, impacting mobility. Its treatment involves a comprehensive approach aimed at managing symptoms and slowing disease progression. It typically includes the use of non-steroidal anti-inflammatory drugs (NSAIDs) to reduce inflammation and pain, and biologic therapies, including TNF inhibitors and IL-17 inhibitors, targeting specific immune system pathways to control inflammation.

Ankylosing Spondylitis Market Trends

• Increasing cases of ankylosing spondylitis (AS) significantly drives the growth of the market.
• As per a study published by European Alliance of Associations for Rheumatology, EULAR 2024, ankylosing spondylitis (AS) is among the most common forms of immune-mediated arthritis, affecting ~0.5% of the population worldwide, except for people of African ancestry where its prevalence is much lower. This surge in prevalence necessitates a higher demand for effective treatments, including biologics, non-steroidal anti-inflammatory drugs (NSAIDs), and physical therapy.
• Consequently, pharmaceutical companies are investing in research and development to introduce innovative therapies, further propelling market expansion.
• Moreover, increased patient awareness and access to healthcare services contribute to early diagnosis and treatment, enhancing the overall management of the disease and fueling market growth.

Ankylosing Spondylitis Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

Based on treatment, the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), biologic therapies, JAK Inhibitors, disease-modifying anti-rheumatic drugs (DMARDs), and corticosteroids. The non-steroidal anti-inflammatory drugs (NSAIDs) segment dominated the market in 2023 and is anticipated to grow at 8% of CAGR over the forecast period.

• NSAIDs are often the first treatment prescribed for ankylosing spondylitis. Thus, they are widely used immediately after diagnosis to manage pain and inflammation effectively. Thereby contributing to their dominant market share.
• Additionally, NSAIDs have been used for decades to treat various inflammatory conditions, including ankylosing spondylitis. Thus, the familiarity and established efficacy contribute to their continued preference and high market share.
• Furthermore, compared to biologics and other advanced therapies, NSAIDs are relatively inexpensive. The affordability of NSAIDs contributes significantly to their widespread use and market dominance.

Based on route of administration, the ankylosing spondylitis market is classified into parenteral and oral. The parenteral segment dominated the market with 56.4% of market share in 2023.

• Parenteral medications often provide faster relief and higher efficacy compared to oral medications which is crucial in managing severe symptoms of ankylosing spondylitis.
• Additionally, the development of biologic therapies, which are predominantly administered via injection, has significantly expanded the parenteral segment. Biologics like TNF inhibitors and IL-17 inhibitors are highly effective in managing ankylosing spondylitis and are predominantly available in injectable forms.
• These factors collectively drive the growth of this segment in the market.

Based on type, the ankylosing spondylitis market is divided into prescription drugs and OTC drugs. In 2023, the prescription drugs segment accounted for USD 4 billion.

• The prescription drugs especially biologics, JAK inhibitors, and disease-modifying anti-rheumatic drugs (DMARDs) are clinically proven to effectively manage ankylosing spondylitis symptoms.
• Additionally, the increased diagnosis of ankylosing spondylitis has led to many patients seeking healthcare provider. Thus, the increased prescription rate of these drugs, further solidifies the dominance of this segment in the market.

Learn more about the key segments shaping this market

 Download Free Sample

Based on application, the ankylosing spondylitis market is categorized into adults and juveniles. The adults segment held highest market share and is poised to reach USD 8.2 billion by 2032.

• Ankylosing spondylitis is typically diagnosed in adulthood, predominantly between the ages of 20 and 40. This age group accounts for the majority of ankylosing spondylitis cases, contributing to the higher market share of treatments tailored for adults.
• Ankylosing spondylitis is a chronic condition that progresses over time. Adults with AS often require ongoing management and treatment to control symptoms and prevent disease progression. This sustained need for treatment among adults drives the demand and market share.

Based on distribution channel, the ankylosing spondylitis market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for significant market share of 45.7% and is expected to witness growth at 7.9% CAGR over the coming years

• Hospitals have access to a wide range of advanced therapies, including biologics, JAK inhibitors, NSAIDs, and other specialized medications used to treat ankylosing spondylitis.
• These treatments are often administered or prescribed by hospital-based rheumatologists, leading to a higher volume of prescriptions filled through hospital pharmacies.

Looking for region specific data?

 Download Free Sample

North America ankylosing spondylitis market size accounted for USD 2.4 billion in 2023 and is predicted to reach USD 4.8 billion by 2032.

• North America boasts advanced healthcare system with well-established rheumatology departments and specialized clinics focused on managing chronic conditions like ankylosing spondylitis. This infrastructure supports timely diagnosis, effective treatment, and comprehensive patient care.
• Favorable regulatory frameworks and reimbursement policies in North America streamline the approval and adoption of new treatments, encouraging pharmaceutical companies to invest in developing and launching innovative therapies. Owing to the above factors, the North America market is expected to witness growth.

The U.S. ankylosing spondylitis market is expected to experience growth at 7.9% CAGR to reach USD 4.3 billion by 2032.

• According to Johns Hopkins Arthritis Center, recent population estimate indicates that the prevalence of ankylosing spondylitis is approximately 0.2-0.5% in U.S.
• Thus, with increasing number of diagnosed cases, there is a heightened demand for ankylosing spondylitis treatments, thereby driving the growth of the country in market.

Germany ankylosing spondylitis market is anticipated to showcase growth in near future.

• Growing awareness of ankylosing spondylitis has led to earlier diagnosis and intervention, driving demand for effective treatments.
• Furthermore, Germany is known for its strong healthcare infrastructure and research capabilities. The availability of innovative therapies, including biologics and targeted therapies, continues to expand the growth of this market.

India ankylosing spondylitis market is poised to witness significant growth between 2024 - 2032.

• India is enhancing its healthcare infrastructure, particularly in urban centers. This improvement supports better access to specialized care and advanced treatments for ankylosing spondylitis patients across the country.
• Furthermore, the presence of key players introducing a wider range of ankylosing spondylitis treatments in Indian market propels the growth of this market.

Ankylosing Spondylitis Market Share

The ankylosing spondylitis industry is highly competitive, driven by a range of pharmaceutical companies that offer diverse treatment options aimed at managing this chronic inflammatory disease. Key players in the market include major pharmaceutical firms and biotechnology companies that specialize in developing and marketing therapies tailored to address the underlying mechanisms of ankylosing spondylitis.

Ankylosing Spondylitis Market Companies

Prominent players operating in the ankylosing spondylitis industry include

• AbbVie, Inc.
• Amgen, Inc.
• Bayer AG
• Eli Lilly and Company
• Horizon Pharma
• Janssen Biotech, Inc.
• Merck & Co., Inc.
• Novartis AG
• PRIMUS PHARMACEUTICALS
• Pfizer, Inc.
• Sandoz Group AG
• UCB, Inc.

Ankylosing Spondylitis Industry News

• In December 2023, UCB announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved BIMZELX (bimekizumab) for the treatment of adults with psoriatic arthritis (PsA), non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS) who are not sufficiently responding to existing treatments. The product launch helped the company to expand its geographic reach and generate revenue.
• In October 2023, Novartis announced the FDA approval of intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). This approval helped the company to broaden its product portfolio and boost its revenue.

The ankylosing spondylitis market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments

Click here to Buy Section of this Report

Market, By Treatment

• Non-steroidal anti-inflammatory drugs (NSAIDs)
• Biologic therapies
  • TNF inhibitors
  • IL-17 inhibitors
• JAK Inhibitors
• Disease-modifying anti-rheumatic drugs (DMARDs)
• Corticosteroids

Market, By Route of Administration

• Parenteral
• Oral

Market, By Type

• Prescription drugs
• OTC drugs

Market, By Application

• Adults
• Juveniles

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa